BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Nordic AML Group - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Nordic AML Group
X-ORIGINAL-URL:https://www.namlg.org
X-WR-CALDESC:Events for Nordic AML Group
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20240312T150000
DTEND;TZID=Europe/Paris:20240312T170000
DTSTAMP:20260526T074401
CREATED:20240213T194106Z
LAST-MODIFIED:20240304T122131Z
UID:10000008-1710255600-1710262800@www.namlg.org
SUMMARY:Nordic AML 'poster walk' post-ASH
DESCRIPTION:Nordic AML posters at ASH 2023 – Webinar – 2024-03-12 – 15:00-16:20 (CET) \nJoin us for a webinar where we delve into the intricacies of showcased Nordic AML posters at the latest ASH Annual Meeting in December 2023. Here we aim for an opportunity to gain valuable insights\, connect with peers\, and stay at the forefront of AML innovation. \n\nJoin via Zoom: https://uu-se.zoom.us/j/63956689621 \n\nTentative agenda (updated 2024-03-04) \n15:00 – 15:05 – Welcome \n15:05 – 15:15 – Elory Leonard\, Stockholm\, Sweden \nProtective Function of Human Skin Mesenchymal Niches for Acute Myeloid Leukemia-Initiating Stem Cells \n15:15 – 15:25 – Ida Vänttinen\, Helsinki\, Finland \nTargeting Venetoclax Resistance in TP53-Mutated Acute Myeloid Leukemia \n15:25 – 15:35 – Claudia Schöllkopf\, Copenhagen\, Denmark \nDose Escalation of HLA-A2-WT1 CD3 T-Cell Bispecific Antibody in a Phase I Study in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) \n15:35 – 15:45 – Sofie Johansson Alm\, Gothenburg\, Sweden \nDeep Sequencing Is a Widely Applicable Tool for Relapse Prediction in Acute Myeloid Leukemia with Mutated NPM1 \n15:45 – 15:55 – Øystein Sefland\, Bergen\, Norway \nIntradermal Vaccination with Vididencel in MRD+ AML-Patients Leads to Increase in Antigen Presenting Cells and T-Cells to the Injection Site\, Visualized Using Imaging Mass Cytometry\, Showing Local Immune Cell Interactions Leading to Systemic Immune Responses \n15:55 – 16:05 – Hanna Duàn\, Helsinki\, Finland \nPrimary Acute Myeloid Leukemia Cells Trigger Distinct Activation Patterns in Expanded NK Cells \n16:05 – 16:15 – Somadri Ghosh\, Lund\, Sweden \nH2-K1 on MLL-AF9 Leukemia Cells Facilitates the Escape of NK Cell-Mediated Immune Surveillance \n16:15 – 16:25 – Jonas Bouhlal\, Helsinki\, Finland \nHigh-Throughput Screens Identify NEDD8 Inhibition As a Strategy to Augment Natural Killer Cell Cytotoxicity Against Blood Cancers \n16:25 – 16:30 – Closing remarks \n\nArranged by the NAMLG Educational Working Group (namlgewg@gmail.com)
URL:https://www.namlg.org/event/nordic-aml-poster-walk-post-ash/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20240321T143000
DTEND;TZID=Europe/Paris:20240321T153000
DTSTAMP:20260526T074401
CREATED:20240312T151714Z
LAST-MODIFIED:20240312T151844Z
UID:10000009-1711031400-1711035000@www.namlg.org
SUMMARY:CCBIO Seminar – Mika Kontro - Functional Screening for Precision Medicine Approaches in AML
DESCRIPTION:Dr. Mika Kontro will discuss the methods for personalizing AML therapies using functional screening. He will provide an overview of the current data implementation and share insights from ongoing prospective trials employing functional screening. Furthermore\, Dr. Kontro will focus on the VenEx trial\, which utilizes ex vivo drug sensitivity testing to identify AML patients who can benefit from the azacitidine-venetoclax regimen. \nMore info can be found on this link. \nJoin via Zoom using this link. \nNo registration necessary.
URL:https://www.namlg.org/event/ccbio-seminar-mika-kontro-functional-screening-for-precision-medicine-approaches-in-aml/
END:VEVENT
END:VCALENDAR